UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 5, 2004
__________
SIGA Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-23047 13-3864870
-------- ------- ----------
(State or other Jurisdiction of (Commission File (I.R.S. Employer
Incorporation or Organization) Number) Identification Number)
420 Lexington Avenue, Suite 601, New York, New York 10170
--------------------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
(212) 672-9100
--------------
(Registrant's telephone number, including area code)
ITEM 7.01. Regulation FD Disclosure.
------------------------
On October 5, 2004, SIGA Technologies, Inc., a Delaware corporation,
issued a press release pursuant to which it announced that the Company's lead
smallpox compound, SIGA-246, has demonstrated significant antiviral activity
against several mouse models of poxvirus disease. A copy of the press release is
attached hereto as Exhibit 99.1, which is incorporated in this Item 7.01 by
reference.
ITEM 9.01 Financial Statements and Exhibits
---------------------------------
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press Release dated October 5, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SIGA TECHNOLOGIES, INC.
By: /s/ Thomas N. Konatich
----------------------------
Thomas N. Konatich
Chief Financial Officer
Date: October 5, 2004
3
EXHIBIT INDEX
-------------
Exhibit Number Description
-------------- -----------
99.1 Press Release dated October 5, 2004.
4